Transient Viral Vector Solution

[On Demand]
Search General Info
Search Education
Search Partnering Companies
Although viral vector manufacturing for late stage clinical and commercial phases ultimately focusses of scalable solutions, all gene therapy projects begin with transient systems. The flexibility of these plasmid-based systems allows optimisation of the therapeutic transgene, the promoter driving its expression, various measures to reduce host immune responses and the targeting of the vector towards specific cell populations.

OXGENE has developed transient vector manufacturing systems for both adeno-associated and lentiviral vectors using its know-how in synthetic biology, cell line engineering and viral vector biomanufacturing. Whilst both systems generate high vector titres, the AAV system also produces capsids with a 30-70 % full rate, making the particles more effective. The LV system benefits from reduced levels of homology between viral vector sequences on different plasmids, making it less likely that replication competent virus is formed. Furthermore, the LV system dovetails nicely with OXGENE’s lentiviral packaging and producer cell lines so that users can transition to these scalable systems when the time is right. OXGENE’s AAV and LV plasmids are available, license-free from OXGENE.

Since joining forces in March 2021, Oxford (UK) based OXGENE and Philadelphia based WuXi Advanced Therapies are now using the same AAV and LV vector production systems making transitioning from preclinical to clinical grade manufacturing an even smoother process.
Speaker
photo
Business Development Manager
OXGENE, a WuXi Advanced Therapies Company